Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Use Of Pre-Approval CV Data From Ongoing Trial Gets Once-Over At Canagliflozin Panel

Jan 21 2013

• By Cathy Dombrowski

Related Content

Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later

Jun 30 2009

Cardiovascular Uncertainty Accompanies Canagliflozin To Advisory Panel

Jan 08 2013

Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking

Jan 07 2013

Recent Round Of Obesity Reviews Suggests CV Safety Standards Have Come Into Focus

May 21 2012

With SPA Finalized, Orexigen To Begin CV Outcomes Study For <em>Contrave</em> In Second Quarter

Feb 06 2012

Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission

Nov 01 2012

Takeda Re-Files DPP-4 Inhibitor Alogliptin, Plays Up Combo With Actos

Aug 01 2011

Alogliptin Rejection Dents Takeda’s Diabetes Franchise

Apr 26 2012

FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs

Dec 22 2008

Related Companies

Johnson & Johnson

Takeda Pharmaceutical Co. Ltd.

Orexigen Therapeutics, Inc.

Novo Nordisk A/S

AstraZeneca PLC

Bristol Myers Squibb Company

Additional Topics

United States Advisory Committees Drug Approval Standards Regulation BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window